Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity

Borden, 2019, Interferons alpha and beta in cancer: Therapeutic opportunities from new insights, Nat Rev Drug Discov, 18, 219, 10.1038/s41573-018-0011-2 Ng, 2016, Alpha and beta type 1 interferon signaling: Passage for diverse biologic outcomes, Cell, 164, 349, 10.1016/j.cell.2015.12.027 van Pesch, 2004, Characterization of the murine alpha interferon gene family, J Virol, 78, 8219, 10.1128/JVI.78.15.8219-8228.2004 Zitvogel, 2015, Type I interferons in anticancer immunity, Nat Rev Immunol, 15, 405, 10.1038/nri3845 Musella, 2017, Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications, Oncoimmunology, 6, 10.1080/2162402X.2017.1314424 Brassard, 2002, Interferon-alpha as an immunotherapeutic protein, J Leukoc Biol, 71, 565, 10.1189/jlb.71.4.565 Muller, 2017, Type I interferons and natural killer cell regulation in cancer, Front Immunol, 8, 304, 10.3389/fimmu.2017.00304 Elion, 2018, Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment, Oncotarget, 9, 29007, 10.18632/oncotarget.25626 Li, 2019, Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy, J Hematol Oncol, 12, 35, 10.1186/s13045-019-0721-x Li, 2018, The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer, J Exp Med, 215, 1287, 10.1084/jem.20180139 van Boxel-Dezaire, 2006, Complex modulation of cell type-specific signaling in response to type I interferons, Immunity, 25, 361, 10.1016/j.immuni.2006.08.014 Ishihara, 2017, Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment, Cancer Immunol Immunother, 66, 281, 10.1007/s00262-016-1914-6 Kulzer, 2014, Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells, J Immunotoxicol, 11, 328, 10.3109/1547691X.2014.880533 Wu, 2017, Modulating both tumor cell death and innate immunity is essential for improving radiation therapy effectiveness, Front Immunol, 8, 613, 10.3389/fimmu.2017.00613 Wilkins, 2019, The immunological consequences of radiation-induced DNA damage, J Pathol, 247, 606, 10.1002/path.5232 Garnett, 2004, Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes, Cancer Res, 64, 7985, 10.1158/0008-5472.CAN-04-1525 Vanpouille-Box, 2017, DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity, Nat Commun, 8, 15618, 10.1038/ncomms15618 Kepp, 2014, Consensus guidelines for the detection of immunogenic cell death, Oncoimmunology, 3, 10.4161/21624011.2014.955691 Formenti, 2013, Combining radiotherapy and cancer immunotherapy: A paradigm shift, J Natl Cancer Inst, 105, 256, 10.1093/jnci/djs629 Azzam, 2012, Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury, Cancer Lett, 327, 48, 10.1016/j.canlet.2011.12.012 Borrego-Soto, 2015, Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer, Genet Mol Biol, 38, 420, 10.1590/S1415-475738420150019 Hu, 2016, The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury, Science, 354, 765, 10.1126/science.aaf7532 Tormoen, 2018, Role of the immunosuppressive microenvironment in immunotherapy, Adv Radiat Oncol, 3, 520, 10.1016/j.adro.2018.08.018 Topalian, 2015, Immune checkpoint blockade: A common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001 Gabrilovich, 2017, Myeloid-derived suppressor cells, Cancer Immunol Res, 5, 3, 10.1158/2326-6066.CIR-16-0297 Mariathasan, 2018, TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Fukumura, 2018, Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges, Nat Rev Clin Oncol, 15, 325, 10.1038/nrclinonc.2018.29 Reid, 1981, Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice, Proc Natl Acad Sci U S A, 78, 1171, 10.1073/pnas.78.2.1171 Gresser, 1983, Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors, J Exp Med, 158, 2095, 10.1084/jem.158.6.2095 Gresser, 1988, Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice, J Exp Med, 168, 1271, 10.1084/jem.168.4.1271 Dunn, 2005, A critical function for type I interferons in cancer immunoediting, Nat Immunol, 6, 722, 10.1038/ni1213 Swann, 2007, Type I IFN contributes to NK cell homeostasis, activation, and antitumor function, J Immunol, 178, 7540, 10.4049/jimmunol.178.12.7540 Diamond, 2011, Type I interferon is selectively required by dendritic cells for immune rejection of tumors, J Exp Med, 208, 1989, 10.1084/jem.20101158 Fuertes, 2011, Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells, J Exp Med, 208, 2005, 10.1084/jem.20101159 Burnette, 2011, The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity, Cancer Res, 71, 2488, 10.1158/0008-5472.CAN-10-2820 Lim, 2014, Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8 (+) T cells, Cancer Immunol Immunother, 63, 259, 10.1007/s00262-013-1506-7 Wu, 2014, Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors, Clin Cancer Res, 20, 644, 10.1158/1078-0432.CCR-13-1334 Wang, 2017, Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy, Cancer Res, 77, 839, 10.1158/0008-5472.CAN-15-3142 Paludan, 2019, DNA-stimulated cell death: Implications for host defense, inflammatory diseases and cancer, Nat Rev Immunol, 19, 141, 10.1038/s41577-018-0117-0 Sun, 2013, Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway, Science, 339, 786, 10.1126/science.1232458 Wu, 2013, Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA, Science, 339, 826, 10.1126/science.1229963 Chow, 2018, RIG-I and other RNA sensors in antiviral immunity, Annu Rev Immunol, 36, 667, 10.1146/annurev-immunol-042617-053309 Woo, 2014, STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors, Immunity, 41, 830, 10.1016/j.immuni.2014.10.017 Deng, 2014, STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors, Immunity, 41, 843, 10.1016/j.immuni.2014.10.019 Hou, 2018, Non-canonical NF-kappaB antagonizes STING sensor-mediated DNA sensing in radiotherapy, Immunity, 49, 490, 10.1016/j.immuni.2018.07.008 Diamond, 2018, Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from irradiated cancer cells to DCs, Cancer Immunol Res, 6, 910, 10.1158/2326-6066.CIR-17-0581 Harding, 2017, Mitotic progression following DNA damage enables pattern recognition within micronuclei, Nature, 548, 466, 10.1038/nature23470 Widau, 2014, RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation, Proc Natl Acad Sci U S A, 111, E484, 10.1073/pnas.1323253111 Ranoa, 2016, Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs, Oncotarget, 7, 26496, 10.18632/oncotarget.8420 Khodarev, 2004, STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells, Proc Natl Acad Sci U S A, 101, 1714, 10.1073/pnas.0308102100 Khodarev, 2007, Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells, Cancer Res, 67, 9214, 10.1158/0008-5472.CAN-07-1019 Weichselbaum, 2008, An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer, Proc Natl Acad Sci U S A, 105, 18490, 10.1073/pnas.0809242105 Khodarev, 2009, STAT1 pathway mediates amplification of metastatic potential and resistance to therapy, PLoS One, 4, e5821, 10.1371/journal.pone.0005821 Khodarev, 2012, Molecular pathways: Interferon/stat1 pathway: Role in the tumor resistance to genotoxic stress and aggressive growth, Clin Cancer Res, 18, 3015, 10.1158/1078-0432.CCR-11-3225 Minn, 2015, Interferons and the immunogenic effects of cancer therapy, Trends Immunol, 36, 725, 10.1016/j.it.2015.09.007 Cheon, 2013, IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage, EMBO J, 32, 2751, 10.1038/emboj.2013.203 Pitroda, 2009, STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect, BMC Med, 7, 68, 10.1186/1741-7015-7-68 Post, 2018, Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer, Clin Cancer Res, 24, 3397, 10.1158/1078-0432.CCR-17-2551 Xia, 2014, NF-kappaB, an active player in human cancers, Cancer Immunol Res, 2, 823, 10.1158/2326-6066.CIR-14-0112 Liang, 2017, Host STING-dependent MDSC mobilization drives extrinsic radiation resistance, Nat Commun, 8, 1736, 10.1038/s41467-017-01566-5 Lemos, 2016, STING promotes the growth of tumors characterized by low antigenicity via IDO activation, Cancer Res, 76, 2076, 10.1158/0008-5472.CAN-15-1456 Monjazeb, 2016, Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies, Clin Cancer Res, 22, 4328, 10.1158/1078-0432.CCR-15-3026 Baird, 2016, Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors, Cancer Res, 76, 50, 10.1158/0008-5472.CAN-14-3619 Dillon, 2019, ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment, Clin Cancer Res, 25, 3392, 10.1158/1078-0432.CCR-18-1821 Deng, 2016, From DNA damage to nucleic acid sensing: A strategy to enhance radiation therapy, Clin Cancer Res, 22, 20, 10.1158/1078-0432.CCR-14-3110 Deng, 2014, Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice, J Clin Invest, 124, 687, 10.1172/JCI67313 Weichselbaum, 2017, Radiotherapy and immunotherapy: A beneficial liaison?, Nat Rev Clin Oncol, 14, 365, 10.1038/nrclinonc.2016.211 Yoshino, 2018, Effects of retinoic acid-inducible gene-I-like receptors activations and ionizing radiation cotreatment on cytotoxicity against human non-small cell lung cancer in vitro, Oncol Lett, 15, 4697 Castiello, 2019, An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation, Cancer Immunol Immunother, 68, 1479, 10.1007/s00262-019-02380-2 Rosenfeld, 2010, A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma, Neuro Oncol, 12, 1071, 10.1093/neuonc/noq071 Ramanjulu, 2018, Design of amidobenzimidazole STING receptor agonists with systemic activity, Nature, 564, 439, 10.1038/s41586-018-0705-y Luo, 2017, A STING-activating nanovaccine for cancer immunotherapy, Nat Nanotechnol, 12, 648, 10.1038/nnano.2017.52 Das, 2019, Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer, Mol Ther, 27, 507, 10.1016/j.ymthe.2018.11.012 Kawai, 2004, Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6, Nat Immunol, 5, 1061, 10.1038/ni1118 Tanaka, 2012, STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway, Sci Signal, 5, ra20, 10.1126/scisignal.2002521